STK11 and non-small cell lung carcinoma: In contrast, Skoulidis et al. concluded in 2018 that STK11/LKB1 genomic changes have a deleterious influence on the clinical responses to PD-1 inhibitors in PDL1-positive NSCLC, suggesting that a lack of response is partially independent of PD-L1 expression [13].